Navigation Links
NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
Date:1/25/2008

software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-lookin
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NuVasive to Host Investor Reception on September 11, 2007
2. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
3. US Oncology Announces Realignment of Executive Team
4. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
5. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
6. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
8. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
9. Accuray Announces New Treatment Planning Service Offering
10. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
11. Sharps Compliance Corp. Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... 2015 , ... The 2015 Market Research Report on the Global Propanol ... global Propanol market with a focus on the Chinese situation. Major companies included in ... ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The ...
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... off marginally legal fireworks, I was feeling a little guilty. ... phone was powered off most of the weekend. Here it ... felt anything but independent of my technologies. , ,Ignoring e-mail ... comes with a penalty of sorting through an over-loaded inbox, ...
... Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd. et al. ... technology providers will function in the future when their ... copyrighted content. , ,The court, in an unanimous decision, ... decision favoring defendants Grokster Ltd. and StreamCast Networks (providers ...
... Trademark law is becoming increasingly important as businesses seek ... that has built up as a result of the ... applications for trademark registration are filed, many of them ... are seen by some as a good leading indicator ...
Cached Biology Technology:Declaring independence from technology (sort of) 2Declaring independence from technology (sort of) 3Tech vendors could be liable for customer behavior - and not just file sharing 2Tech vendors could be liable for customer behavior - and not just file sharing 3Why file for trademark protection? 2Why file for trademark protection? 3Why file for trademark protection? 4
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/9/2015)... Calif. , July 9, 2015 /PRNewswire/ ... leading developer of human interface solutions, today ... the industry,s first fully hardware encapsulated fingerprint ... secure authentication technology is literally off the ... and biometric matching within the fingerprint sensor ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... of Toronto is revealing biochemical processes responsible for diseases ... the way for pharmaceutical applications. , A study ... describes how U of T and Johns Hopkins University ... play an important role in human health and disease. ...
... scientists for a dog snapper is actually a new ... of the South Atlantic Ocean. , The international science ... new snapper species that belongs to the Lutjanidae family, ... Kenyon Lindeman of Environmental Defense. The study published in ...
... Angelman syndrome are often seen laughing and smiling, but ... movement problems and seizures. , ,ew research ... could be alleviated. , Edwin Weeber, Ph.D., and ... of Angelman syndrome by preventing the inhibition of CaMKII, ...
Cached Biology News:Technology reveals 'lock and key' proteins behind diseases 2New species of snapper discovered in Brazil 2Angelman syndrome deficits rescued in mice 2Angelman syndrome deficits rescued in mice 3
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... easy grip) Mfr Desig: ...
... with 1 or 2 color(s), suitable for ... spotted on standard slides combining performance with ... three different models:, ... scanner (635nm and 532nm). , ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (R4026) ... assistance. Material: cap polystyrene ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,515-8) ...
Biology Products: